Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 9.80
-0.27 (-2.68%)
Jul 10, 2026, 4:00 PM EST
Knight Therapeutics Employees
Knight Therapeutics had 830 employees as of December 31, 2025. The number of employees increased by 85 or 11.41% compared to the previous year.
Employees
830
Change (1Y)
85
Growth (1Y)
11.41%
Revenue / Employee
615.00K CAD
Profits / Employee
6.76K CAD
Market Cap
988.67M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 830 | 85 | 11.41% | 830 | 0 |
| Dec 31, 2024 | 745 | 20 | 2.76% | 745 | 0 |
| Dec 31, 2023 | 725 | 27 | 3.87% | 725 | 0 |
| Dec 31, 2022 | 698 | 38 | 5.76% | 698 | 0 |
| Dec 31, 2021 | 660 | -19 | -2.80% | 660 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Green Thumb Industries | 4,900 |
| Verano Holdings | 3,800 |
| Cresco Labs | 2,900 |
| Canopy Growth | 1,128 |
| Organigram Global | 1,120 |
| TerrAscend | 1,038 |
| Aurora Cannabis | 1,028 |
| Cronos Group | 610 |
Knight Therapeutics News
- 23 days ago - Knight Therapeutics Announces Repayment of Revolving Credit Facility - GlobeNewsWire
- 6 weeks ago - Knight to Present at the Jefferies 2026 Healthcare Conference in New York City - GlobeNewsWire
- 6 weeks ago - Knight Therapeutics Announces Launch of TAVALISSE® in Mexico - GlobeNewsWire
- 2 months ago - Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City - GlobeNewsWire
- 2 months ago - Knight Therapeutics price target raised to C$9.50 from C$8.50 at RBC Capital - TheFly
- 2 months ago - Knight Therapeutics resumed with a Buy at Canaccord - TheFly
- 2 months ago - Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil - GlobeNewsWire
- 2 months ago - Knight Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts